Vtama is a cream used to treat plaque psoriasis and eczema. You rub a thin layer onto the patches of skin once a day. It works by switching on a sensor in skin cells that helps calm inflammation, and it is not a steroid.
Every report comes from a Lived member, sent anonymously.
Have you tried Vtama (Tapinarof) for Psoriasis?
Tapinarof, sold as Vtama, is a prescription cream for two common inflammatory skin conditions. It is approved for plaque psoriasis in adults, where thick, red, scaly patches form on the skin, and for atopic dermatitis (eczema) in adults and children 2 years and older, where the skin becomes dry, itchy and inflamed. It has not been shown to be safe and effective for psoriasis in children. Tapinarof is not a steroid. It was the first medicine in a newer class called aryl hydrocarbon receptor agonists, and it adds another topical choice alongside steroid creams and other nonsteroidal treatments. The studies behind its approval mostly involved people whose skin disease covered a limited part of the body.
Skin cells and immune cells contain a protein called the aryl hydrocarbon receptor (AhR). When something activates it, the receptor acts as a switch that turns genes on or off, including genes that regulate inflammation and keep tissues in balance. Psoriasis and eczema both involve inflammation in the outer layer of skin and disruption of the proteins that form the skin's protective barrier. Tapinarof activates this receptor in the skin where it is applied, and over weeks the redness, scaling or itch can settle. The label notes that exactly how this produces the benefit is not fully understood. Very little of the cream reaches the bloodstream in adults; in most blood samples from psoriasis studies the drug was too low to measure.
Vtama comes as a 1% cream. It is applied once a day as a thin layer to the patches of affected skin only, rather than to surrounding healthy skin. Wash your hands afterward unless you are treating your hands. The cream is for use on the skin only. Keep it out of the eyes, mouth and vagina. In the clinical trials it was used on patches anywhere on the body, and the prescriber will advise on how long to continue and how to handle flares or clearing.
The most common side effect is folliculitis: small red bumps or pimple-like spots around hair follicles where the cream is applied. In the psoriasis trials, about 1 in 5 people using tapinarof developed it. Irritation or an itchy rash at the treated skin (contact dermatitis), headache and cold-like symptoms were also more frequent than with the plain cream base. In the psoriasis studies, folliculitis and contact dermatitis were the main reasons a small number of people stopped treatment. In the eczema studies, which were mostly in children, colds and other respiratory infections, headache, and occasionally wheezing, vomiting or ear infections were reported more often than with the cream base. Young children aged 2 to 6 had colds and ear infections more often than older users. Hives occurred rarely. Let the prescriber know if bumps, rash or itching at the treated areas are bothersome or keep spreading, since adjusting or switching treatment may help.
Because so little tapinarof is absorbed, it is not known to interact with other medicines, and the label lists no situations in which it must never be used. It is still worth telling the prescriber about other skin products and treatments you use on the same areas. There is not enough information to know whether tapinarof affects a pregnancy, or whether it passes into breast milk and affects a nursing baby. People who are pregnant, planning a pregnancy or breastfeeding should weigh the need for treatment with their clinician.
Improvement builds gradually over several weeks. In the main trials, about 4 in 10 adults with psoriasis had clear or almost clear skin after 12 weeks of daily use, compared with about 6 in 100 using the plain cream. In the eczema trials, about 45% of participants reached clear or almost clear skin after 8 weeks, compared with roughly 14 to 18% on the plain cream, and many older children and adults reported much less itching. Many people improve without fully clearing, and it has not been compared directly with steroid creams or other topical treatments. In longer studies of up to about a year, side effects were similar to those seen early on. Some people whose skin cleared completely stopped the cream and stayed clear for a while: a median of about 4 months for psoriasis and about 2 months for eczema before the condition returned to mild. Psoriasis and eczema are long-term conditions, so a plan for flares and follow-up visits matters.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Vtama (Tapinarof), what you've noticed, or ask the community a question.